TRYNGOLZA
Ionis Claims Curative Potential for Tryngolza in Severe Triglyceride Disease
Ionis; Tryngolza; severe hypertriglyceridemia; curative potential; triglyceride reduction; acute pancreatitis; antisense oligonucleotide; FDA submission; Phase III trial; RNA-targeted therapy
Ionis Builds Case for Wider Tryngolza Use in Severe Lipid Disorders Following Positive Phase 3 Results
Ionis Pharmaceuticals; Tryngolza; olezarsen; severe hypertriglyceridemia; lipid disorder; Phase 3 trial; familial chylomicronemia syndrome; acute pancreatitis; FDA; drug indication expansion
Ionis Posts Strong Results for Tryngolza in Severe Blood Fat Disease
Ionis Pharmaceuticals; Tryngolza; olezarsen; hypertriglyceridemia; triglycerides; Phase III Essence study; FDA approval; familial chylomicronemia syndrome; cardiovascular risk reduction; drug launch
Breakthrough in Familial Chylomicronemia Syndrome: FDA Approves Ionis’ Tryngolza as First Treatment
Familial Chylomicronemia Syndrome (FCS), Ionis Tryngolza, FDA Approval, Rare Genetic Hyperlipidemia, Acute Pancreatitis, Lipid-Lowering Therapy
FDA Approves Ionis’s TRYNGOLZA for Familial Chylomicronemia Syndrome, a Rare Metabolic Disorder
FDA approval, Ionis Pharmaceuticals, TRYNGOLZA, olezarsen, familial chylomicronemia syndrome (FCS), rare metabolic disorder